Literature DB >> 18392849

Does the proper intravenous immunoglobulin substitution in primary immunodeficiency protect against HBV infections?: a description of a case series.

Glück Joanna1, Zeglen Slawomir, Rymarczyk Barbara, Rogala Barbara.   

Abstract

There are no recommendations concerning preoperative management of primary immunodeficiency patients in cases of emergency or planned surgery in relation to risk of hepatitis type B virus infection. To assess if immunodeficient patients regularly supplemented with immunoglobulins are protected against hepatitis B. IgG, IgM and IgA total levels and anti-HBs level were estimated in adult patients with primary humoral immunodeficiency before and after immunoglobulins supplementation according to a standardized schedule. Serum IgG and anti-HBs level significantly increased after immunoglobulin supplementation. Anti-HBs titer increased in all cases over 100 IU/L regardless of initial total IgG serum value, reaching a highly protective level. There was no correlation between increase in concentration of IgG (DeltaIgG) versus Deltaanti-HBs in the studied patients. Patients with primary hypogammaglobulinemia supplemented with immunoglobulin are protected against hepatitis type B.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392849     DOI: 10.1007/s00430-008-0075-4

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  9 in total

Review 1.  Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies.

Authors: 
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  Intravenous immune globulins: an update for clinicians.

Authors:  Irina Knezevic-Maramica; Margot S Kruskall
Journal:  Transfusion       Date:  2003-10       Impact factor: 3.157

Review 3.  Primary immunodeficiency diseases in adulthood.

Authors:  D S Riminton; S Limaye
Journal:  Intern Med J       Date:  2004-06       Impact factor: 2.048

4.  Agammaglobulinemia.

Authors:  O C BRUTON
Journal:  Pediatrics       Date:  1952-06       Impact factor: 7.124

5.  IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period.

Authors:  J Daily; B Werner; R Soiffer; J Fingeroth
Journal:  Bone Marrow Transplant       Date:  1998-04       Impact factor: 5.483

6.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

7.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

Authors:  Alessandro Remo Zanetti; Andrea Mariano; Luisa Romanò; Raffaele D'Amelio; Maria Chironna; Rosa Cristina Coppola; Mario Cuccia; Rossana Mangione; Fosca Marrone; Francesco Saverio Negrone; Antonino Parlato; Emanuela Zamparo; Carla Zotti; Tommaso Stroffolini; Alfonso Mele
Journal:  Lancet       Date:  2005 Oct 15-21       Impact factor: 79.321

8.  Familial microcephaly with normal intelligence, immunodeficiency, and risk for lymphoreticular malignancies: a new autosomal recessive disorder.

Authors:  E Seemanová; E Passarge; D Beneskova; J Houstĕk; P Kasal; M Sevcíková
Journal:  Am J Med Genet       Date:  1985-04

9.  Control of hepatitis B in central and eastern Europe (CEE) and the Newly Independent States (NIS): recommendations of the October 1996 meeting in Siófok, Hungary.

Authors:  A Meheus
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

  9 in total
  1 in total

1.  Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.

Authors:  Soyoung Lee; Han Wool Kim; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.